Literature DB >> 15157556

Thyroglobulin: a specific serum marker for the management of thyroid carcinoma.

Ronald J Whitley1, Kenneth B Ain.   

Abstract

Thyroglobulin measurements in tissue and serum play an integral role in the evaluation of patients who have thyroid cancer. Immunohistochemical detection of thyroglobulin in surgical specimens is useful in the differential diagnosis of tumors of unknown origin; however, the most important application of thyroglobulin measurement in clinical practice is in the postsurgical management of differentiated thyroid cancer. Serum thyroglobulin is a highly specific and sensitive tumor marker for detecting persistent or recurrent thyroid cancer and for monitoring clinical status. The reappearance of circulating thyroglobulin after total thyroid ablation is pathognomonic for the presence of tumor. The measurement of thyroglobulin in serum is challenging, however, and several analytical problems limit assay performance. Thyroglobulin autoantibody interference is a particularly significant concern that requires all thyroglobulin samples to be screened for their presence. No immunoassay is totally free from interference by thyroglobulin autoantibodies. Measurement of thyroglobulin mRNA to detect circulating tumor cells may help to overcome some of the limitations of current protein-detection methods; serum thyroglobulin will continue to remain the "gold standard." The complex functional features of thyroid carcinomas make sole reliance upon any one diagnostic technique, including thyroglobulin assessments, potentially misleading. Thyroglobulin measurements are a critical component of a multifaceted diagnostic approach to this disease.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15157556     DOI: 10.1016/j.cll.2004.01.001

Source DB:  PubMed          Journal:  Clin Lab Med        ISSN: 0272-2712            Impact factor:   1.935


  20 in total

1.  Quantification of thyroglobulin, a low-abundance serum protein, by immunoaffinity peptide enrichment and tandem mass spectrometry.

Authors:  Andrew N Hoofnagle; Jessica O Becker; Mark H Wener; Jay W Heinecke
Journal:  Clin Chem       Date:  2008-09-18       Impact factor: 8.327

2.  In vitro assays to test the interference of anti-thyroglobulin antibodies on thyroglobulin measurement.

Authors:  Deolinda Madureira; Susana Prazeres; Márcia São Pedro; Teresa Pereira; Ana Paula Font; Maria João Bugalho
Journal:  Endocrine       Date:  2008-03-29       Impact factor: 3.633

3.  Current concepts and future directions in differentiated thyroid cancer.

Authors:  Donald S A McLeod
Journal:  Clin Biochem Rev       Date:  2010-02

4.  Markedly elevated thyroglobulin levels in the preoperative thyroidectomy patient correlates with metastatic burden.

Authors:  Sarah C Oltmann; Glen Leverson; Suzy Hsiu-I Lin; David F Schneider; Herbert Chen; Rebecca S Sippel
Journal:  J Surg Res       Date:  2013-12-18       Impact factor: 2.192

Review 5.  Radioiodine-remnant ablation in low-risk differentiated thyroid cancer: pros.

Authors:  Kenneth B Ain
Journal:  Endocrine       Date:  2015-06-25       Impact factor: 3.633

6.  Meta-analysis of radiofrequency ablation for treating the local recurrence of thyroid cancers.

Authors:  Q Zhao; G Tian; D Kong; T Jiang
Journal:  J Endocrinol Invest       Date:  2016-03-15       Impact factor: 4.256

7.  Management of thyroid cancers.

Authors:  Devendra A Chaukar; Anuja D Deshmukh; Mitali R Dandekar
Journal:  Indian J Surg Oncol       Date:  2010-11-21

8.  RUNX3 site-specific hypermethylation predicts papillary thyroid cancer recurrence.

Authors:  Dan Wang; Wei Cui; Xiaoyan Wu; Yiping Qu; Na Wang; Bingyin Shi; Peng Hou
Journal:  Am J Cancer Res       Date:  2014-11-19       Impact factor: 6.166

9.  Diagnosis of a previously unidentified primary site in patients with spinal metastasis: diagnostic usefulness of laboratory analysis, CT scanning and CT-guided biopsy.

Authors:  Yoichi Iizuka; Haku Iizuka; Satoshi Tsutsumi; Yumi Nakagawa; Takashi Nakajima; Yasunori Sorimachi; Tsuyoshi Ara; Masahiro Nishinome; Takayuki Seki; Kenji Takagishi
Journal:  Eur Spine J       Date:  2009-06-16       Impact factor: 3.134

10.  A list of candidate cancer biomarkers for targeted proteomics.

Authors:  Malu Polanski; N Leigh Anderson
Journal:  Biomark Insights       Date:  2007-02-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.